GSK/Novartis Support For Benefiber Claims Too Thin To Convince NARB
This article was originally published in The Tan Sheet
Referring to rather than providing two studies was GSK/Novartis' downfall in arguing before the National Advertising Review Board to support Benefiber regularity claims. GSK/Novartis questions the panel’s "refusal to accept the full translations of two confirmatory studies referred to in the record."
Register for our free email digests: